These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3398239)

  • 1. Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study.
    Miyajima S; Aizawa Y; Matsuoka A; Okabe M; Shibata A
    Jpn Heart J; 1988 Jan; 29(1):115-9. PubMed ID: 3398239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
    Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
    J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained ventricular tachycardia responsive to verapamil in patients with hypertrophic cardiomyopathy. Clinical and electrophysiological assessment of drug efficacy.
    Miyajima S; Aizawa Y; Suzuki K; Satoh M; Niwano S; Ebe K; Fujita T; Ishiguro J; Hirokawa Y; Shibata A
    Jpn Heart J; 1989 Mar; 30(2):241-9. PubMed ID: 2724542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
    Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
    J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death.
    Watson RM; Schwartz JL; Maron BJ; Tucker E; Rosing DR; Josephson ME
    J Am Coll Cardiol; 1987 Oct; 10(4):761-74. PubMed ID: 3655144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.
    Pernat A; Pohar B; Horvat M
    J Electrocardiol; 1997 Oct; 30(4):341-4. PubMed ID: 9375912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
    Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
    Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
    Meltzer RS; Robert EW; McMorrow M; Martin RP
    Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
    Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
    G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
    O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
    Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy.
    Kowey PR; Eisenberg R; Engel TR
    N Engl J Med; 1984 Jun; 310(24):1566-9. PubMed ID: 6539421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of biventricular pacing on left ventricular outflow tract pressure gradient in a patient with hypertrophic cardiomyopathy and normal interventricular conduction.
    Komsuoglu B; Vural A; Agacdiken A; Ural D
    J Cardiovasc Electrophysiol; 2006 Feb; 17(2):207-9. PubMed ID: 16533259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
    Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
    Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
    Kimball BP; Bui S; Wigle ED
    Am Heart J; 1993 Jun; 125(6):1691-7. PubMed ID: 8498312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
    Haruki S; Minami Y; Suzuki A; Hagiwara N
    Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients.
    Fananapazir L; Tracy CM; Leon MB; Winkler JB; Cannon RO; Bonow RO; Maron BJ; Epstein SE
    Circulation; 1989 Nov; 80(5):1259-68. PubMed ID: 2805263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.
    Sherrid M; Delia E; Dwyer E
    Am J Cardiol; 1988 Nov; 62(16):1085-8. PubMed ID: 3189171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed electrical stimulation in patients with hypertrophic cardiomyopathy.
    Kuck KH; Kunze KP; Geiger M; Costard A; Schlüter M
    Z Kardiol; 1987; 76 Suppl 3():131-6. PubMed ID: 3433865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.